ASND Relative Valuation
ASND's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ASND is overvalued; if below, it's undervalued.
Historical Valuation
Ascendis Pharma A/S (ASND) is now in the Undervalued zone, suggesting that its current forward PS ratio of 11.50 is considered Undervalued compared with the five-year average of -19.25. The fair price of Ascendis Pharma A/S (ASND) is between 183.65 to 261.20 according to relative valuation methord. Compared to the current price of 177.20 USD , Ascendis Pharma A/S is Undervalued By 3.51%.
Relative Value
Fair Zone
183.65-261.20
Current Price：177.20
3.51%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
-48.09
P/B
Median3y
-18.21
Median5y
-7.61
-2.42
FCF Yield
Median3y
-7.18
Median5y
-6.63
Competitors Valuation Multiple
The average P/S ratio for ASND's competitors is 7.09, providing a benchmark for relative valuation. Ascendis Pharma A/S Corp (ASND) exhibits a P/S ratio of 11.50, which is 62.24% above the industry average. Given its robust revenue growth of 5.28%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Ascendis Pharma A/S (ASND) currently overvalued or undervalued?
What is Ascendis Pharma A/S (ASND) fair value?
How does ASND's valuation metrics compare to the industry average?
What is the current P/B ratio for Ascendis Pharma A/S (ASND) as of Jul 18 2025?
What is the current FCF Yield for Ascendis Pharma A/S (ASND) as of Jul 18 2025?
What is the current Forward P/E ratio for Ascendis Pharma A/S (ASND) as of Jul 18 2025?